AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	277.90M
Revenue (ttm)	198.51M
Net Income (ttm)	11.61M
Shares Out	104.87M
EPS (ttm)	0.10
PE Ratio	26.05
Forward PE	18.31
Dividend	0.02 (0.62%)
Ex-Dividend Date	Jun 19, 2024

Volume	2,058
Average Volume	21,038
Open	2.640
Previous Close	2.600
Day's Range	2.640 - 2.650
52-Week Range	2.370 - 3.420
Beta	0.42
RSI	50.62
Earnings Date	May 22, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. The company has collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. AFT Pharma...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 110
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2023, AFT Pharmaceuticals's revenue was 195.41 million, an increase of 24.75% compared to the previous year's 156.64 million. Earnings were 15.61 million, an increase of 46.51%.